← back to search

Joseph Jankovic

Phillips University · US
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Joseph Jankovic, M.D. is Professor of Neurology, Distinguished Chair in Movement Disorders, and Founder and Director of the Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC), Department of Neurology, Baylor College of Medicine, Houston, Texas. After completing his Neurology training at Columbia University, New York City, he joined the faculty of Baylor College of Medicine in 1977. Since that time he has led clinical and research team that focuses on etiology, pathophysiology, and experimental therapeutics of Parkinson’s disease and related neurodegenerative and movement disorders such as tremors, dystonia, Tourette syndrome, Huntington disease, restless legs syndrome, tardive dyskinesia, and paroxysmal dyskinesias. Under the direction of Dr.
h-index
156
citations
105,451
works
1,475
NIH funding
primary concept
email

Recent publications

Yawning-related tremor in patients with Parkinson's disease.
2026cited by 0position: contributordoi
The "Hallett Sign" of Functional Jerky Movement Disorder.
2026cited by 0position: contributordoi
Mark Hallet (1943–2025)
Neurology 2026cited by 0position: contributordoi
Genome-Wide Association Analysis of Tic Disorders Reveals 6 Independent Risk Loci and Highlights Tic-Associated Cell Types and Brain Circuitry
2026cited by 0position: contributordoi
Skin Phosphorylated Alpha-Synuclein in Patients With Essential Tremor
Neurology Open Access 2026cited by 0position: contributordoi
Definition and Classification of Dystonia
Movement Disorders 2025cited by 75position: middledoi
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Pharmacological Research 2025cited by 16position: middledoi
Tardive dyskinesia versus tardive syndrome. What is in a name?
2025cited by 2position: contributordoi
Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.
2025cited by 1position: contributordoi
Response to the letter "Reassessing the hypothesis of essential tremor as a prodromal feature of Parkinson's disease".
2025cited by 0position: contributordoi
Corticobasal Syndrome: Are There Central or Peripheral Triggers?
2025cited by 0position: contributordoi
Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson’s Disease
2025cited by 0position: contributordoi
Extrapyramidal System/Symptoms/Signs Should Be Retired.
2024cited by 4position: contributordoi
Essential tremor as a prodromal feature of Parkinson's disease.
2024cited by 3position: contributordoi
Leg stereotypy syndrome: phenomenological and quantitative analysis.
2024cited by 0position: contributordoi
Isolated Cervical Dystonia: Diagnosis and Classification
Movement Disorders 2023cited by 85position: middledoi
Linking the cerebellum to Parkinson disease: an update.
2023cited by 61position: contributordoi
Isolated Cervical Dystonia: Diagnosis and Classification.
2023cited by 60position: contributordoi
Embracing Monogenic Parkinson's Disease: The <scp>MJFF</scp> Global Genetic <scp>PD</scp> Cohort
Movement Disorders 2023cited by 49position: middledoi
COVID19-associated new-onset movement disorders: a follow-up study
Journal of Neurology 2023cited by 20position: middledoi
Peripherally-induced Movement Disorders: An Update.
2023cited by 15position: contributordoi
How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
2023cited by 10position: contributordoi
The Clinical Characterization of Blocking Tics in Patients With Tourette Syndrome.
2023cited by 4position: contributordoi
Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review
Dystonia 2022cited by 37position: middledoi
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
npj Parkinson s Disease 2022cited by 18position: middledoi
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease
Expert Review of Neurotherapeutics 2022cited by 17position: lastdoi
The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases?
2022cited by 12position: contributordoi
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
2022cited by 8position: contributordoi
Essential tremor
Nature Reviews Disease Primers 2021cited by 153position: middledoi
Botulinum Toxin in Movement Disorders: An Update
Toxins 2021cited by 140position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 27 papers (2020–2026)Mark Hallett · National Institute of Neurological Disorders and Stroke10 papers (2012–2025)Cynthia Comella · Rush University Medical Center10 papers (2012–2023)Joel S. Perlmutter · Washington University in St. Louis9 papers (2016–2021)José Fidel Baizabal‐Carvallo · Hospital Regional de Alta Especialidad del Bajío8 papers (2012–2019)Stephen G. Reich · University of Maryland, Baltimore8 papers (2015–2021)Brian D. Berman · Virginia Commonwealth University7 papers (2017–2021)Connie Marras · University Health Network6 papers (2014–2019)Kailash P. Bhatia · University of Zurich6 papers (2013–2025)Anthony E. Lang · Istituti di Ricovero e Cura a Carattere Scientifico6 papers (2013–2026)Marie Vidailhet · Centre National de la Recherche Scientifique6 papers (2017–2025)Benzi M. Kluger · University of Rochester Medical Center5 papers (2015–2019)Richard L. Barbano · University of Rochester Medical Center5 papers (2016–2021) · 5 papers (2013–2025)Victor S.C. Fung · The University of Sydney5 papers (2013–2025)Rajesh Pahwa · University of Kansas5 papers (2012–2018)Eng‐King Tan · National University of Singapore5 papers (2020–2025)Stewart A. Factor · Emory University5 papers (2014–2021)William G. Ondo · Houston Methodist4 papers (2012–2019)Deborah A. Hall · Rush University4 papers (2016–2019)